| [1] |
Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v 1.0, Cancer Incidence and Mortality Worldwide[EB/OL].[2015-3-24].http:/ /globocan.iarc.fr/Default.aspx.
|
| [2] |
Bouganim N, Tsvetkova E, Clemons M, et al. Evolution of sites of recurrence after early breast cancer over the last 20 years: implications for patient care and future research[J].Breast Cancer Res Treat,2013,139(2):603-606.
|
| [3] |
Houssami N, Morrow M. Margins in breast conservation: a clinician’s perspective and what the literature tells us[J]. J Surg Oncol,2014,110(1):2-7,
|
| [4] |
Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised,multicentre, open-label, phase 3 non-inferiority trial [J].Lancet Oncol,2014,15(12):1303-1310.
|
| [5] |
Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC Study[J]. J Clin Oncol,2015,33(3):258-264.
|
| [6] |
Boughey JC, Suman VJ, Mittendorf EA, et al. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance)[J]. Ann Surg,2015,261(3):547-552.
|
| [7] |
Budach W, Kammers K, Boelke E, et al. Adjuvant radiotherapy of regional lymph nodes in breast cancer - a metaanalysis of randomized trials[J]. Radiat Oncol,2013,8(14):267.
|
| [8] |
Polley MY, Leung SC, McShane LM, et al. An international Ki67 reproducibility study[J]. J Natl Cancer Inst,2013,105(24):1897-1906.
|
| [9] |
Polley MY, Leung SC, Gao D, et al. An international study to increase concordance in Ki67 scoring[J]. Mod Pathol, 2015,28(6):778-786.
|
| [10] |
Yi M, Huo L, Koenig KB, et al. Which threshold for ER positivity? A retrospective study based on 9639 patients[J].Ann Oncol,2014,25(5):1004-1011.
|
| [11] |
Pagani O,Regan MM, Walley BA,et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer[J]. N Engl J Med,2014,371(2):107-118.
|
| [12] |
Francis PA, Regan MM, Fleming GF, et al. Adjuvant Ovarian Suppression in Premenopausal Breast Cancer[J]. N Engl J Med,2015,372(17):436-446.
|
| [13] |
Sestak I, Dowsett M, Zabaglo L, et al. Factors predicting late recurrence for estrogen receptor positive breast cancer[J]. J Natl Cancer Inst,2013,105(19):1504-1511.
|
| [14] |
Dubsky P, Brase JC, Jakesz R,et al. The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients[J]. Br J Cancer,2013,109(12):2959-2964.
|
| [15] |
Zhang Y, Schnabel CA, Schroeder BE, et al. Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early-and late-distant recurrence[J].Clin Cancer Res,2013,19(15):4196-4205.
|
| [16] |
Moore HC,Unger JM,Phillips KA,et al. Goserelin for ovarian protection during breast-Cancer adjuvant chemotherapy[J]. N Engl J Med,2015,372(10):923-932.
|
| [17] |
Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer[J]. N Engl J Med,2015,372(2):134-141.
|
| [18] |
Sikov WM, Berry DA, Perou CM,et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-perweek paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603(Alliance)[J]. J Clin Oncol,2015,33(1):13-21.
|
| [19] |
von Minckwitz G, Schneeweiss A, Loibl S,et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial[J]. Lancet Oncol,2014,15(7):747-756.
|
| [20] |
Loibl S. Primary systemic therapy for clinicians: medical and research perspectives[EB/OL]. (2015-03-19)[2015-3-24].http:/ /ac.els-cdn.com/S0960977615700305/1-s2.0-S096097 7615700305-main. pdf? _ tid = a3517740-06a7-11e5-b203-00000aab0f27&acdnat = 1432975457 _ aa59fd0fda144a25b57 a7b1e9f8bbd88.
|